Tags

Type your tag names separated by a space and hit enter

Porphyria cutanea tarda, C282Y, H63D and S65C HFE gene mutations and hepatitis C infection: a study from southern France.
Dermatology. 2003; 206(3):212-6.D

Abstract

BACKGROUND

To evaluate the role of genetic factors in the pathogenesis of porphyria cutanea tarda (PCT) and their association with chronic hepatitis C.

OBJECTIVE

To investigate the relations between hemochromatosis gene (HFE) mutations and PCT in the south of France and their links with chronic hepatitis C virus (HCV) infection.

METHODS

The genotype for the C282Y, H63D and S65C mutations of HFE was determined in 33 patients with PCT, 46 patients with HCV infection but without PCT and 58 controls. Iron status and HCV, HBV and HIV serologies were studied in all patients.

RESULTS

A statistically significant increase in the C282Y mutation was found in PCT patients. No difference was found for H63D or S65C mutations. The prevalence of HCV infection was higher in PCT patients than controls.

CONCLUSIONS

C282Y mutations and HCV infection but not H63D or S65C mutations are PCT-triggering or associated factors in the south of France.

Authors+Show Affiliations

Department of Dermatology, Archet-2 Hospital, Nice, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

12673077

Citation

Chiavérini, Christine, et al. "Porphyria Cutanea Tarda, C282Y, H63D and S65C HFE Gene Mutations and Hepatitis C Infection: a Study From Southern France." Dermatology (Basel, Switzerland), vol. 206, no. 3, 2003, pp. 212-6.
Chiavérini C, Halimi G, Ouzan D, et al. Porphyria cutanea tarda, C282Y, H63D and S65C HFE gene mutations and hepatitis C infection: a study from southern France. Dermatology. 2003;206(3):212-6.
Chiavérini, C., Halimi, G., Ouzan, D., Halfon, P., Ortonne, J. P., & Lacour, J. P. (2003). Porphyria cutanea tarda, C282Y, H63D and S65C HFE gene mutations and hepatitis C infection: a study from southern France. Dermatology (Basel, Switzerland), 206(3), 212-6.
Chiavérini C, et al. Porphyria Cutanea Tarda, C282Y, H63D and S65C HFE Gene Mutations and Hepatitis C Infection: a Study From Southern France. Dermatology. 2003;206(3):212-6. PubMed PMID: 12673077.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Porphyria cutanea tarda, C282Y, H63D and S65C HFE gene mutations and hepatitis C infection: a study from southern France. AU - Chiavérini,Christine, AU - Halimi,Gilles, AU - Ouzan,Denis, AU - Halfon,Philippe, AU - Ortonne,Jean-Paul, AU - Lacour,Jean-Philippe, PY - 2002/04/15/received PY - 2002/08/14/accepted PY - 2003/4/4/pubmed PY - 2003/9/10/medline PY - 2003/4/4/entrez SP - 212 EP - 6 JF - Dermatology (Basel, Switzerland) JO - Dermatology VL - 206 IS - 3 N2 - BACKGROUND: To evaluate the role of genetic factors in the pathogenesis of porphyria cutanea tarda (PCT) and their association with chronic hepatitis C. OBJECTIVE: To investigate the relations between hemochromatosis gene (HFE) mutations and PCT in the south of France and their links with chronic hepatitis C virus (HCV) infection. METHODS: The genotype for the C282Y, H63D and S65C mutations of HFE was determined in 33 patients with PCT, 46 patients with HCV infection but without PCT and 58 controls. Iron status and HCV, HBV and HIV serologies were studied in all patients. RESULTS: A statistically significant increase in the C282Y mutation was found in PCT patients. No difference was found for H63D or S65C mutations. The prevalence of HCV infection was higher in PCT patients than controls. CONCLUSIONS: C282Y mutations and HCV infection but not H63D or S65C mutations are PCT-triggering or associated factors in the south of France. SN - 1018-8665 UR - https://www.unboundmedicine.com/medline/citation/12673077/Porphyria_cutanea_tarda_C282Y_H63D_and_S65C_HFE_gene_mutations_and_hepatitis_C_infection:_a_study_from_southern_France_ L2 - https://www.karger.com?DOI=10.1159/000068895 DB - PRIME DP - Unbound Medicine ER -